

**Announcement of Listing of “FENTOS® TAPE,”
a transdermal, long-acting cancer pain relief patch, on the NHI Drug Price Standard
~ To be launched on June 24, 2010 ~**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu, Saga, President and CEO: Hirotaka Nakatomi, hereinafter, “Hisamitsu Pharmaceutical”) and Kyowa Hakko Kirin Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, President: Yuzuru Matsuda, hereinafter, “Kyowa Hakko Kirin”) announce that “FENTOS® TAPE,” a transdermal, long-acting cancer pain relief patch, marketing approval of which was obtained in April 2010, is now listed on the NHI Drug Price Standard as of June 11, 2010. FENTOS® TAPE is scheduled to be launched on June 24, 2010.

Hisamitsu Pharmaceutical and Kyowa Hakko Kirin concluded the joint marketing agreement for Japan in June 2008. After the launch of the product, based on the agreement, Hisamitsu Pharmaceutical will market the product, while distribution of the product and information provision and gathering activities will be conducted by both the companies (one brand and two channels).

FENTOS® TAPE is a narcotic ethical (Rx) pharmaceutical product developed as a transdermal patch of fentanyl citrate, a synthetic narcotic that exhibits significant analgesic effects, using Hisamitsu Pharmaceutical’s TDDS (Transdermal Drug Delivery System) technology. This patch has drug release properties suitable for a single daily application.

Since FENTOS® has a clinical advantage of allowing easier adherence to the basic principles of opioid analgesics (“by the clock”) that require evaluation of pain and observation of the presence of adverse reactions every 24 hours, and scheduled administration at a predetermined time of the day, it is expected to exert stable and sustained analgesic effects.

Both Hisamitsu Pharmaceutical and Kyowa Hakko Kirin hope to contribute to the improvement of quality of life in patients suffering from cancer pain by providing adequate and appropriate information about this drug in the future.